Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

124.23 USD
+9.54 (+8.32%)
As of 2:29 AM IST
chart
Previous Close 114.69
Open 116.58
Volume 406,710
3m Avg Volume 110,369
Today’s High 126.03
Today’s Low 116.58
52 Week High 220.09
52 Week Low 77.60
Shares Outstanding (mil) 3.26
Market Capitalization (mil) 4,400.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
140
FY17
238
FY16
1
FY15
9
EPS (USD)
FY18
-0.575
FY17
-0.183
FY16
-0.274
FY15
-0.139
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
16.21
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
59.72
17.74
LT Debt to Equity (MRQ)
vs sector
59.72
13.15
Return on Investment (TTM)
vs sector
-57.59
14.22
Return on Equity (TTM)
vs sector
-77.45
15.99

EXECUTIVE LEADERSHIP

John Oyler
Chairman of the Board, Chief Executive Officer, Founder, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Wendy Yan
Senior Vice President, Head of Regulatory Affairs, Since 2014
Salary: $68,510.00
Bonus: --
Jason Yang
Senior Vice President, Head of Clinical Development, Since 2014
Salary: $116,129.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Ozannes Corporate Se
94 Solaris Avenue, Camana Bay
BEIJING   BEJ   KY1-1108

Phone: +1345.9494123
Site:

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

SPONSORED STORIES